Introduction: Few studies have examined the association between continuous glucose monitoring (CGM) metrics and hospital-related clinical outcomes in the inpatient setting.

Methods: In this prospective observational study, patients admitted on non-intensive care floors receiving fingerstick glucose monitoring wore blinded Dexcom G6 Pro CGM during their hospital stay. Clinical data were extracted from the medical record including a composite of infection, DKA/HHS, renal replacement therapy, or thrombosis. Readmissions and emergency department (ED) visits within 30 days of discharge were identified through record review and participant phone interview. The associations between CGM metrics and clinical outcomes were assessed with multivariable logistic regression.

Results: In this cohort of 326 adults (78% type 2 diabetes, 12% type 1 diabetes, 10% other), median % time in range 70-180 mg/dL was 44.5% (17.1, 70.2%), % time >180 mg/dL (TAR) was 54.8% (28.8, 82.3%), and % time <70 mg/dL (TBR) was 0% (0, 0.2%). Multivariable regression analyses demonstrated a significant association of 30-day ED visits with increased %TAR (p = 0.01) and borderline association of 30-day readmissions and %TBR (p = 0.06) (Table 1).

Conclusion: Hyperglycemia identified by CGM was associated with 30-day ED visits, suggesting CGM could help identify patients that may benefit from increased support after hospital discharge.

graphic
View largeDownload slide
Disclosure

K.L. Flint: None. M. O'Connor: None. A. Sabean: None. A. Ashley: None. H. Zheng: None. J. Yan: None. B. Steiner: None. N. Anandakugan: None. M.M. Calverley: None. R. Bartholomew: None. E. Greaux: None. L.E. Castellanos: None. M.E. Larkin: None. S.J. Russell: Employee; Beta Bionics, Inc. Stock/Shareholder; Beta Bionics, Inc. Other Relationship; Beta Bionics, Inc. Consultant; Beta Bionics, Inc. Research Support; Beta Bionics, Inc. Consultant; Novo Nordisk. Research Support; Novo Nordisk. Other Relationship; Novo Nordisk. M.S. Putman: Research Support; Dexcom, Inc. Other Relationship; Vertex Pharmaceuticals Incorporated. Research Support; Vertex Pharmaceuticals Incorporated. Advisory Panel; Anagram Therapeutics.

Funding

National Institutes of Health (R01 DK119699-02S1); National Institutes of Health (T32DK007028); Dexcom Investigator Initiated Study Grant

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.